Patheon has added new filling technology at its Milton Park, UK facility, to reduce the time needed for formulation development and stability testing. The Xcelodose 600 S Automated Encapsulator supports early-phase development for oral dose products.

The Xcelodose 600 S, allows for manufacturing active pharmaceutical ingredients (API), in capsule form, for Phase I through pilot-scale Phase II clinical trials. The technology fills the API directly into capsules, with no need for excipients, and may save up to six months of development time by reducing the need for formulation development and stability testing. The Xcelodose technology provides filling speeds of more than 600 capsules per hour.

Patheon's Milton Park facility focuses on the development and formulation of semi-solid, oral liquid and solid dosage forms for early-stage development. Its pharmaceutical development services operations provide integrated services ranging from pre-formulation, formulation, analytical development, clinical trial material manufacturing and packaging, and scale-up, including biopharmaceuticals.

Source: Patheon